Beste apotheek van Nederland

Clough J. CNS-targeted sexual dysfunction drug for men and
women. Drug Discov Today 2002;7(9):492-494.
Coelho O R. Tolerability and safety profile of sildenafil citrate
(Viagra) in Latin American patient populations. Int J Impot Res
2002;14(Suppl 2):54-59.
Coker C, Bettocchi C, Pryor J. Caverject, a new licensed
prostaglandin preparation for use in erectile dysfunction. J
Androl 1994;15(6 SUPPL.):71S
Coleman C I, Carabino J M, Vergara C M et al. Vardenafil.
Hosp Formul 2003;38(3):131-148.
Collazos J, Martinez E, Mayo J et al. Sexual dysfunction in
HIV-infected patients treated with highly active antiretroviral
therapy. Journal of Acquired Immune Deficiency Syndromes:
JAIDS 2002;31(3):322-326.
Colp G M, Scroppo F I. Can self-directed pelvic floor exercises
improve erectile function?. Nature Clinical Practice Urology
2005;2(3):128-129.
Conti C R, Pepine C J, Sweeney M. Efficacy and safety of
sildenafil citrate in the treatment of erectile dysfunction in
patients with ischemic heart disease. Am J Cardiol
1999;83(5A):29C-34C.
Contreras L N, Masini A M, Danna M M et al. Glucocorticoids:
their role on gonadal function and LH secretion. Minerva
Endocrinol 1996;21(2):43-46.
Cooper A J, Losztyn S, Russell N C et al. Medroxyprogesterone
acetate, nocturnal penile tumescence, laboratory arousal, and
sexual acting out in a male with schizophrenia. Arch Sex Behav
1990;19(4):361-372.
Cormio L, Nisen H, Ruutu M et al. Etilefrine in the prevention
of prolonged erection after diagnostic pharmacological
stimulation. Ann Chir Gynaecol 1996;85(3):247-250.
Corona G, Mannucci E, Petrone L et al. ANDROTEST: a
structured interview for the screening of hypogonadism in
patients with sexual dysfunction. Br J Sex Med 2006;3(4):706­
715.
Corona G, Mannucci E, Petrone L et al. Association of
hypogonadism and type II diabetes in men attending an
outpatient erectile dysfunction clinic. Int J Impot Res
2006;18(2):190-197.
Corona G, Mannucci E, Schulman C et al. Psychobiologic
correlates of the metabolic syndrome and associated sexual
dysfunction. Eur Urol 2006;50(3):595-604.
Creasey G H. Lecture 6: restoration of male sexual function
following spinal cord injury. Int J Impot Res 2000;12 Suppl
3S54-S55.
Crum-Cianflone N F, Bavaro M, Hale B et al. Erectile
dysfunction and hypogonadism among men with HIV. AIDS
Patient Care & Stds 2007;21(1):9-19.
Culha M, Mutlu N, Acar O et al. Patient-partner
satisfaction with intracavernous medication supported
with oral agents in selected cases of Peyronie's
disease: A ten-month follow-up study. International
Urology & Nephrology 1999;31(2):257-262.
Curri S B, Menchini Fabris F. Evidence and results
obtained with a new Trans-Epidermal Barrier (T.E.B.)
drug in the medical treatment of vascular impotence.
Boll Chim Farm 1996;135(5):316-334.
Cyranoski D. Malaysian researchers bet big on homegrown
Viagra. Nat Med 2005;11(9):912
Czuriga I, Riecansky I, Bodnar J et al. Comparison of
the New Cardioselective Beta-Blocker Nebivolol with
Bisoprolol in Hypertension: The Nebivolol, Bisoprolol
Multicenter Study (NEBIS). Cardiovascular Drugs &
Therapy 2003;17(3):257-263.
Dang G, Matern R, Bivalacqua T J et al. Intralesional
interferon-alpha-2B injections for the treatment of
Peyronie's disease. South Med J 2004;97(1):42-46.
Davis B E, Weigel J W, Whitford C S. Treatment of
male impotence: a new option. Kans Med
1990;91(12):325-326.
Davis J M. American College of
Neuropsychopharmacology - 43rd annual meeting. 12­
16 December 2004, San Juan, Puerto Rico. IDrugs
2005;8(2):100-103.
Davis M E, Brewster M E. Cyclodextrin-based
pharmaceutics: Past, present and future. Nat Rev
Genet 2004;3(12):1023-1035.
De Meyer J M, Oosterlinck W. Influence of the
method of intracavernous injection on penile rigidity:
a possible pharmacokinetic explanation. Urology
1997;49(2):248-252.
De Rosa M, Zarrilli S, Vitale G et al. Six months of
treatment with cabergoline restores sexual potency in
hyperprolactinemic males: an open longitudinal study
monitoring nocturnal penile tumescence. Journal of
Clinical Endocrinology & Metabolism
2004;89(2):621-625.
De Tejada I. Vardenafil Duration of Action. Eur Urol
2006;50(5):901-902.
De Tejada I, Garvey D S, Schroeder J D et al. Design
and evaluation of nitrosylated alpha-adrenergic
receptor antagonists as potential agents for the
treatment of impotence. Journal of Pharmacology &
Experimental Therapeutics 1999;290(1):121-128.
Degirmenci B, Acar M, Albayrak R et al. Effects of
sildenafil citrate (Viagra) on renal arteries: An
evaluation with Doppler ultrasound. Urol Int
2006;77(2):170-172.
D-192